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Abstract
Agmatine has neuroprotective effects on retinal ganglion cells (RGCs) as well as cortical and spinal neurons. It protects RGCs 
from oxidative stress even when it is not present at the time of injury. As agmatine has high affinity for various cellular recep-
tors, we assessed protective mechanisms of agmatine using transformed RGCs (RGC-5 cell line). Differentiated RGC-5 cells 
were pretreated with 100 μM agmatine and consecutively exposed to 1.0 mM hydrogen peroxide (H2O2). Cell viability was 
determined by measuring lactate dehydrogenase (LDH), and the effects of selective alpha 2-adrenergic receptor antagonist 
yohimbine (0-500 nM) and N-methyl-D-aspartic acid (NMDA) receptor agonist NMDA (0-100 µM) were evaluated. Agmatine’s 
protective effect was compared to a selective NMDA receptor antagonist MK-801. After a 16-h exposure to H2O2, the LDH assay 
showed cell loss greater than 50%, which was reduced to about 30% when agmatine was pretreated before injury. Yohimbine 
almost completely inhibited agmatine’s protective effect, but NMDA did not. In addition, MK-801 (0-100 µM) did not significantly 
attenuate the H2O2-induced cytotoxicity. Our results suggest that neuroprotective effects of agmatine on RGCs under oxidative 
stress may be mainly attributed to the alpha 2-adrenergic receptor signaling pathway.
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Glaucoma is the leading cause of irreversible blindness 
worldwide. Although elevated intraocular pressure has been 
known as a major risk factor for the development and pro-
gression of glaucoma, oxidative stress is also associated 
with glaucomatous visual field deterioration (1-3). Retinal 
ganglion cells (RGCs) are susceptible to oxidative stress 
(3-5). As glaucomatous damages are mostly irreversible, 
many glaucoma researchers are searching for a neuropro-
tective strategy for RGCs.
Agmatine is a primary amine, which is formed by decar-
boxylation of L-arginine in the mammalian brain. Agmatine 
has high affinity for various cellular receptors. It is an agonist 
for alpha 2-adrenergic and imidazoline receptors and an 
antagonist for N-methyl-D-aspartic acid (NMDA) receptors 
(6-8). Agmatine has neuroprotective effects against cortical 
and spinal neuronal injuries (9-11). It also protects RGCs 
from hypoxic damage (12). Even when agmatine is not 
present at the time of injury, it seems to protect RGCs by 
later blocking cellular death induced by oxidative stress (13). 
However, the precise protective mechanisms of agmatine 
pretreatment have not been well established.
We investigated the mechanisms of action of agmatine 
pretreatment on RGCs under oxidative stress using trans-
formed RGCs (RGC-5 cell line).
Material and Methods
Cell culture and agmatine pretreatment
RGC-5 cells, which belong to a transformed RGC line 
developed from postnatal Sprague-Dawley rats, were 
cultured in Dulbecco’s modified Eagle’s medium (DMEM; 
Gibco, USA) plus 10% heat-inactivated fetal bovine serum 
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(FBS; Gibco), 100 U/mL penicillin, and 100 µg/mL strepto-
mycin (Gibco). For differentiation, the cells were incubated 
with 1.0 μM staurosporine (Sigma-Aldrich, USA) for 6 h; 
and then they were cultured in 10% FBS-DMEM for another 
3 days (13).
After differentiation, the cells were pretreated with 100 μM 
agmatine (Sigma-Aldrich) in serum-free DMEM for 2 h (13), 
and then rinsed with phosphate-buffered saline (PBS; Gibco). 
Control cells were incubated in serum-free DMEM.
Oxidative stress with agonist/antagonist
After agmatine (100 μM) pretreatment for 2 h, the cells 
were exposed to 1.0 mM hydrogen peroxide (H2O2; Sigma-
Aldrich) for 16 h (13). The mechanisms of action of agmatine 
pretreatment were investigated using the specific alpha 
2-adrenergic receptor antagonist yohimbine (0-500 nM; 
Sigma-Aldrich), and NMDA receptor agonist NMDA (0-100 
μM; Calbiochem, USA). In addition, the effect of agmatine 
was compared to that of MK-801 (0-100 µM; Sigma-Aldrich), 
a selective NMDA receptor antagonist.
Cytotoxicity assay
Cell viability was determined by measuring lactate dehy-
drogenase (LDH; CytoTox 96® Non-Radioactive Cytotoxic-
ity Assay Kit; Promega, USA) according to manufacturer 
instruction. Briefly, the LDH released from injured cells 
into the culture medium was reacted with tetrazolium salt. 
The red formazan product was measured at 490 nm using 
an ELISA plate reader (Vmax; Molecular Device, USA). 
Cytotoxicity was calculated as the proportion of injured 
cells to the total cell population (14). Data are reported as 
means ± SEM.
Statistical analysis 
Data were analyzed by one-way ANOVA, followed by 
post hoc comparisons (Student-Newman-Keuls) using the 
Statistical Package for Social Sciences (SPSS) program for 
Windows, version 12.0 (SPSS Inc., USA). P values below 
0.05 were considered to be significant.
Results
Differentiated RGC-5 cells were pretreated with 100 
μM agmatine for 2 h, and then exposed to 1.0 mM H2O2 
for 16 h for induction of oxidative stress. After agmatine 
pretreatment, the cytotoxicity of H2O2 declined from above 
50 to approximately 30% (Figure 1A,B).
Neither yohimbine nor NMDA, at any concentration, 
had any significant effect on oxidative stress-induced cell 
death (data not shown); 10 nM yohimbine and 100 μM 
NMDA were used for further experiments. While yohimbine 
almost completely blocked the protective effects of agmatine 
pretreatment (Figure 1A), NMDA did not (Figure 1B).
To evaluate the contribution of NMDA receptor signal-
ing, the protective effect of agmatine was compared to that 
of MK-801. MK-801 did not significantly affect the H2O2-
induced cytotoxicity of RGC-5 cells (Figure 1C).
Discussion
Agmatine is known to be an agonist for alpha 2-adren-
ergic and imidazoline receptors as well as an antagonist of 
NMDA receptors (6-8). Wheeler and WoldeMussie (15) and 
Kalapesi et al. (16) studied the alpha 2-adrenergic receptors 
of human ganglion cells and the RGC-5 cell line. They dem-
Figure 1. Determination of H2O2 cytotoxicity by the lactate de-
hydrogenase assay. Differentiated RGC-5 cells were pretreated 
with 100 μM agmatine and then exposed to oxidative stress with 
yohimbine (A) or N-methyl-D-aspartic acid (NMDA) (B). The cells 
were also treated with MK-801 (C). Panels A and B, *P < 0.05 
(one-way ANOVA followed by post hoc comparisons).
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onstrated the presence of alpha 2A-adrenergic receptors 
on both undifferentiated and succinyl concanavalin-A dif-
ferentiated RGC-5s. They also showed a higher expression 
of alpha 2A-adrenergic receptors on 7-day differentiated 
RGC-5 cells compared to the undifferentiated and early 
differentiated cells. In addition, RGCs also expressed NMDA 
glutamate receptors.
In the present study, the protective effects of agmatine 
pretreatment on RGC-5s under oxidative stress were 
completely abolished by 10 nM yohimbine but only partially 
decreased by 100 µM NMDA. Even the powerful NMDA 
antagonist MK-801 did not reduce the RGC-5 cell death 
induced by H2O2. These results suggest that agmatine 
pretreatment may rescue RGCs from oxidative stress mainly 
through alpha 2-adrenergic signaling rather than through 
the NMDA receptor pathway.
We have demonstrated that agmatine pretreatment 
has anti-apoptotic effects on differentiated RGC-5s under 
oxidative stress (13). In the present study, its protective 
mechanisms were investigated. Considering the many 
biological functions of agmatine, this study is not sufficient 
since its focus was limited to alpha 2-adrenergic and NMDA 
receptor pathways. Further experiments are needed to fully 
understand the neuroprotective mechanisms of agmatine 
pretreatment.
The neuroprotective mechanisms of agmatine pre-
treatment on RGCs under oxidative stress in vitro may be 
mainly associated with the alpha 2-adrenergic receptor 
signaling pathway. 
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